350% rise in demand for daily Wegovy weight-loss pill

27 July 2026

Three weeks after the UK launch of Danish pharma major Novo Nordisk’s (NOV: N) daily Wegovy Pill (semaglutide), weight health provider CheqUp says early demand indicates strong consumer interest in a clinically supported oral alternative to injectable weight-loss medication.

CheqUp has seen demand for the pill grow by 350% in the weeks following pre-sale and launch. The provider says interest has continued to build as awareness grows that an oral treatment may be a viable option for eligible patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK